uniQure N.V. - 8-K Filing
FDA accepts Biologics License Application for ifezuntirgene inilparvovec for Huntington’s disease with Priority Review and a PDUFA date of May 1, 2027. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $QURE
Read the full article at SEC EDGAR
Part of the story InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook (23 articles)